VERAXA Biotech AG, a portfolio company of Xlife Sciences AG (SIX: XLS), announced it has secured $27.5 million in senior secured convertible note financing from High Trail Capital LP and entered into a share purchase agreement with Lincoln Park Capital Fund LLC for up to $50 million in equity financing. The financing arrangements are designed to strengthen VERAXA’s financial position ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market.
The High Trail Capital financing includes a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share. The equity line with Lincoln Park Capital provides VERAXA with discretionary access to capital over a 24-month period without warrants or participation rights. The company stated that the combined financing structure supports continued development of its antibody-based therapeutic pipeline, including proprietary BiTAC formats and antibody-drug conjugates.
This financing is crucial for VERAXA as it prepares to go public via a SPAC merger. The capital infusion will enable the company to advance its drug discovery and development engine for antibody drug conjugates and novel antibody-based therapies. VERAXA originates from scientific discoveries at the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research.
Xlife Sciences, as the parent company, focuses on incubating and accelerating promising research projects from universities and research institutions in the life sciences sector, aiming to provide solutions for high unmet medical needs. The successful financing and planned Nasdaq listing could significantly boost VERAXA's visibility and access to capital markets, potentially accelerating the development of its pipeline.
For investors, this move signals confidence from institutional investors like High Trail Capital and Lincoln Park Capital in VERAXA's technology and business model. The equity line provides a flexible capital source without immediate dilution, while the convertible note offers near-term funding. However, the warrants and conversion features could lead to future dilution for existing shareholders.
The biotech industry closely watches such financing structures as indicators of company health and future prospects. VERAXA's ability to secure substantial funding ahead of its listing suggests strong investor interest in its antibody-based therapies, which could have significant implications for cancer treatment and other therapeutic areas.
For more information, visit the full press release at https://ibn.fm/oxUOU. Details about VERAXA Biotech AG are available at https://www.veraxa.com/, and about Xlife Sciences AG at https://www.xlifesciences.ch.
